Drug Trial Radar · NCT06935357
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
454
Planned (sponsor's estimate)
Start
May 8, 2025
Primary completion
May 31, 2027
Study completion Jun 5, 2029
Sponsor
- Lead sponsor
- BiogenBiogen (BIIB)
- Sponsor type
- Industry
- First posted
- Apr 20, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In this study, researchers will learn more about the use of felzartamab in participants with immunoglobulin A nephropathy (IgAN). IgAN is a kidney disease caused by the buildup of an antibody called IgA in the kidneys over time. In people with IgAN, abnormal IgA and other antibodies form clusters that build up in the small filters of the kidneys, which leads to inflammation and damage. Felzartamab is designed to target certain immune cells that produce these abnormal antibodies. This study will focus on participants who have protein in their urine (proteinuria) as a result of damaged kidneys. The main goal of the study is to learn about the effect felzartamab has on proteinuria. The main question that researchers want to answer is: • How much does the amount of protein in the urine change from the start of the study to Week 36? Researchers will learn about the effect felzartamab has on the kidneys' ability to filter blood. They will also learn more about the safety of felzartamab and how it is processed by the body. The study will be done as follows: * Participants will be screened to check if they can join the study. * Participants will be randomized to receive either felzartamab or a placebo. A placebo looks like the study drug but contains no real medicine. * Neither the researchers nor the participants will know what the participants will receive. * Participants will receive felzartamab or placebo as intravenous (IV) infusions. The treatment period will last 24 weeks. * Afterwards, participants will enter a follow-up period which will last 80 weeks. * In total, participants will have 17 study visits. Participants will stay in the study for about 2 years.
Conditions
- Immunoglobulin A Nephropathy (IgAN)
Interventions
FelzartamabDrug
Administered IV
PlaceboDrug
Administered IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change From Baseline in Proteinuria as Measured by the Urine Protein: Creatinine Ratio (UPCR)Time frame: Baseline up to Week 36
Locations
265 sites in 28 countries. Site status is shown where the registry gives one.
Applied Research Center of Arkansas
Little Rock, Arkansas · Recruiting
Kidney & Hypertension Center - Apple Valley
Apple Valley, California · Recruiting
Scripps Green Hospital
Carlsbad, California · Recruiting
National Institute of clinical Research Administration Office
Garden Grove, California · Withdrawn
UCLA Health David Geffen School of Medicine
Los Angeles, California · Recruiting
FOMAT Medical Research - FOMAT - PPDS
Oxnard, California · Recruiting
North America Research Institute-San Dimas
San Dimas, California · Recruiting
Nova Clinical Research, LLC
Bradenton, Florida · Recruiting
University of Florida - Gainesville - 1600 SW Archer Rd
Gainesville, Florida · Recruiting
Royal Research, Corp.
Hollywood, Florida · Recruiting
Central Florida Kidney Specialists
Orlando, Florida · Recruiting
CDC Research Institute, LLC
Port Saint Lucie, Florida · Recruiting
American Clinical Trials LLC
Acworth, Georgia · Withdrawn
The Vasculitis and Glomerulonephritis Center at Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Brigham and Women's Hospital
Boston, Massachusetts · Recruiting
UMass Memorial Medical Center
Worcester, Massachusetts · Recruiting
Henry Ford Hospital
Detroit, Michigan · Recruiting
Elixia Health - Michigan Kidney Consultants, LLC - Elixia - PPDS
Pontiac, Michigan · Withdrawn
Anointed Nephrology and HTN - SKYCRNG - PPDS
Brookhaven, Mississippi · Recruiting
Midwest Nephrology Associates,Inc.
City of Saint Peters, Missouri · Withdrawn
Icahn School of Medicine at Mount Sinai
New York, New York · Recruiting
James J Peters Veterans Administration Medical Center - NAVREF - PPDS
The Bronx, New York · Recruiting
Penn Renal Electrolyte and Hypertension Perelman
Philadelphia, Pennsylvania · Not yet recruiting
Lifespan at Rhode Island Hospital
Providence, Rhode Island · Recruiting
Knoxville Kidney Center, PLLC
Knoxville, Tennessee · Recruiting
Texas Kidney Institute - Dallas
Dallas, Texas · Recruiting
Provecta Research Network
Houston, Texas · Recruiting
R & H Clinical Research
Katy, Texas · Recruiting
Medical College of Wisconsin, Inc.
Milwaukee, Wisconsin · Recruiting
Consultorios Médicos Dr. Doreski - Fundacion Respirar - PPDS
Buenos Aires, Argentina · Recruiting
DOM Centro de Reumatología
Buenos Aires, Argentina · Recruiting
Maffei Centro Médico
Buenos Aires, Argentina · Not yet recruiting
Clínica de Nefrología Urología Y Enfermedades Cardiovasculares
Santa Fe, Argentina · Recruiting
Hospital General de Agudos Dr. Cosme Argerich
La Boca, Buenos Aires F.D., Argentina · Recruiting
Hospital Italiano de Buenos Aires
Almagro, Ciudad Autónoma de BuenosAires, Argentina · Recruiting
INECO Neurociencias Oroño
Rosario, Santa Fe Province, Argentina · Recruiting
CIMER-Centro Integral de Medicina Respiratoria
San Miguel de Tucumán, Tucumán Province, Argentina · Recruiting
John Hunter Hospital
New Lambton, New South Wales, Australia · Recruiting
Concord Repatriation General Hospital
New South Wales, New South Wales, Australia · Recruiting
Royal North Shore Hospital-Reserve Road
St Leonards, New South Wales, Australia · Recruiting
Showing 40 of 265 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.